title: High-dose therapy with autologous stem cell support for lymphoma--from experimental to standard treatment.
abstract: High-dose therapy with autologous stem cell support (HDT) has been a therapeutic option for lymphomas in Norway since as far back as 1987. By restoring bone marrow function through reinfusion of the patient's own stem cells, it is possible to administer cancer treatment in higher and otherwise lethal doses, and thereby achieve better treatment results. Originally stem cells were harvested from bone marrow and the high-dose therapy included total body irradiation, but since the mid 1990s stem cells have been harvested by apheresis and the high-dose therapy has consisted of chemotherapy alone (BEAM chemotherapy). In 1995 the treatment was regionalised and since then it has been performed in all health regions. The HDT procedure was introduced as an experimental treatment in clinical studies with international collaboration. The indications have changed over time, and this is now established treatment for a number of types of lymphoma.
authors.forename: Knut Bjøro
authors.initials: KB
authors.lastname: Smeland
authors.forename: Cecilie E
authors.initials: CE
authors.lastname: Kiserud
authors.forename: Grete F
authors.initials: GF
authors.lastname: Lauritzsen
authors.forename: Alexander
authors.initials: A
authors.lastname: Fosså
authors.forename: Jens
authors.initials: J
authors.lastname: Hammerstrøm
authors.forename: Vidar
authors.initials: V
authors.lastname: Jetne
authors.forename: Arne
authors.initials: A
authors.lastname: Kolstad
authors.forename: Gunnar
authors.initials: G
authors.lastname: Kvalheim
authors.forename: Jon Håvard
authors.initials: JH
authors.lastname: Loge
authors.forename: Turid
authors.initials: T
authors.lastname: Løkeland
authors.forename: Jon Magnus
authors.initials: JM
authors.lastname: Tangen
authors.forename: Harald
authors.initials: H
authors.lastname: Holte
authors.forename: Stein
authors.initials: S
authors.lastname: Kvaløy
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000266:history* / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000266:history; D019091:Critical Pathways; D018380:Hematopoietic Stem Cell Transplantation / Q000266:history*; D049673:History, 20th Century; D006801:Humans; D008223:Lymphoma / Q000266:history / Q000628:therapy*; D009664:Norway; D017410:Practice Guidelines as Topic; D014182:Transplantation, Autologous / Q000266:history